2017 WKD Theme Kidney Disease & Obesity Obesity is defined as abnormal or excessive fat accumulation that may impair health. In 2014, worldwide over 600 million adults were obese. Obesity is a potent risk factor for the development of kidney disease. It increases the risk of developing major risk factors of Chronic Kidney Disease (CKD), like diabetes and hypertension, and it has a direct impact on the development of CKD and end stage renal disease (ESRD): in individuals affected by obesity, the kidneys have to work harder, filtering more blood than normal (hyperfiltration) to meet the metabolic demands of the increased body weight. The increase in function can damage the kidney and raise the risk of developing CKD in the long-term. The good news is that obesity, as well as CKD, is largely preventable. Education and awareness of the risks of obesity and a healthy lifestyle, including proper nutrition and exercise, can dramatically help in preventing obesity and kidney disease. This year World Kidney Day promotes education about the harmful consequences of obesity and its association with kidney disease, advocating healthy lifestyle and health policy measures that make preventive behaviors an affordable option. In this context, Dr. Csaba Kovesdy, Dr. Susan Furth and Dr. Carmine Zoccali have written the editorial. This paper provides an excellent summary and rationale for WKD 2017, whose focus is on the relationship between obesity and kidney disease. 11, 2017 — Diabetes is known to increase a person's risk of kidney disease. Now, a new study suggests that the converse also is true: kidney dysfunction. Did you know that African Americans are 3 times more likely to experience kidney failure? Because kidney disease often has no symptoms, it can go unnoticed until it. ![]() ![]() “Obesity is a growing worldwide epidemic. Obesity is one of the strongest risk factors for new-onset chronic kidney disease, and also for nephrolithiasis and for kidney cancer. This year the World Kidney Day promotes education on the harmful consequences of obesity and its association with kidney disease, advocating healthy lifestyle and health policy measures that make preventive behaviors an affordable option.” To access the article, click The relation between Kidney Disease and Obesity Kidney disease is more likely to develop in obese people including in those with diabetes and hypertension. By 2025, obesity will affect 18% of men and over 21% of women worldwide, and that severe obesity will affect 6% of all men and 9% of all women around the world. In some nations, obesity is already present in more than one-third of the adult population and contributes significantly to overall poor health and high annual medical costs. In the general population, obesity increases the risk of death and contributes to many other diseases such as heart disease, diabetes, hypertension, high cholesterol, obstructive sleep apnea, fatty liver, gall bladder disease, osteoarthritis, various cancers, mental disorders, and poor quality of life. A growing body of evidence indicates that obesity is also a potent risk factor for the development of chronic kidney disease (CKD) and end-stage renal disease (ESRD). People who are overweight or obese have 2 to 7 more chances of developing ESRD compared to those of normal weight. Obesity may lead to CKD both indirectly by increasing type 2 diabetes, hypertension and heart disease, and also by causing direct kidney damage by increasing the workload of the kidneys and other mechanisms. Reducing obesity may reverse or slow CKD progression. Acute kidney injury (AKI) is a serious condition that develops suddenly, often lasts a short time and may disappear completely once the underlying cause has been treated, but it can also have long-lasting consequences with life-long problems. AKI occurs more frequently in obese people. References: • WHO Obesity: • The Lancet: • Obesity, hypertension, and chronic kidney disease International Journal of Nephrology and Renovascular Disease • • Lancet 2016: • Current Opinion in Nephrology and Hypertension 2016: • Annals of Internal Medicine 2006. The mission of Danone Research is to bring health through food to the greatest number of people. With 150 manufacturing sites and over 75,000 employees, Danone is a health food leader. The waters division of the Danone Group encompasses several well known international brands including Evian, Volvic, Badoit and Bonafont, as well as leading national brands such as Aqua (Indonesia), Villavicencio, Villa del Sur (Argentina), Zywiec Zdroj (Poland), Hayat (Turkey), Fontvella, Lanjaron (Spain), Salus (Uruguay), Robust, Health (China) and Salvetat (France). Danone is committed to promoting healthy hydration. Our aim is to encourage scientific advances in hydration studies, and ensure the diffusion and application of this information through our the Hydration for Health Initiative. Vifor Fresenius Medical Care Renal Pharma The partner of choice for renal pharmaceuticals and innovative, patient-focused solutions Vifor Fresenius Medical Care Renal Pharma is a strategic partnership between Vifor Pharma and Fresenius Medical Care, and a rapidly-growing international company that focuses on nephrology. The company develops and commercialises high quality, innovative products that help patients with chronic kidney disease (CKD) to manage their condition and to live better, healthier and more fulfilling lives. We work in partnership with specialist clinics, healthcare professionals, payors and patients to offer them the most comprehensive portfolio of nephrology products. These cover five essential therapeutic areas: anaemia management; mineral & bone disorders management; cardio-renal management; CKD progression and kidney transplantation. Vifor Fresenius Medical Care Renal Pharma is the partner of choice for innovative nephrology products. By combining pharmaceutical expertise and day-to-day understanding of the patient experience, Vifor Fresenius Medical Care Renal Pharma is continually seeking new ways to improve treatment options for clinicians and to drive better patient care, working to complement our unrivalled portfolio of nephrology medicines with new technologies and treatment modalities to provide truly integrated solutions. The mission of Danone Research is to bring health through food to the greatest number of people. With 150 manufacturing sites and over 75,000 employees, Danone is a health food leader. The waters division of the Danone Group encompasses several well known international brands including Evian, Volvic, Badoit and Bonafont, as well as leading national brands such as Aqua (Indonesia), Villavicencio, Villa del Sur (Argentina), Zywiec Zdroj (Poland), Hayat (Turkey), Fontvella, Lanjaron (Spain), Salus (Uruguay), Robust, Health (China) and Salvetat (France). Danone is committed to promoting healthy hydration. Our aim is to encourage scientific advances in hydration studies, and ensure the diffusion and application of this information through our the Hydration for Health Initiative. Vifor Fresenius Medical Care Renal Pharma The partner of choice for renal pharmaceuticals and innovative, patient-focused solutions Vifor Fresenius Medical Care Renal Pharma is a strategic partnership between Vifor Pharma and Fresenius Medical Care, and a rapidly-growing international company that focuses on nephrology. The company develops and commercialises high quality, innovative products that help patients with chronic kidney disease (CKD) to manage their condition and to live better, healthier and more fulfilling lives. We work in partnership with specialist clinics, healthcare professionals, payors and patients to offer them the most comprehensive portfolio of nephrology products. These cover five essential therapeutic areas: anaemia management; mineral & bone disorders management; cardio-renal management; CKD progression and kidney transplantation. Vifor Fresenius Medical Care Renal Pharma is the partner of choice for innovative nephrology products. By combining pharmaceutical expertise and day-to-day understanding of the patient experience, Vifor Fresenius Medical Care Renal Pharma is continually seeking new ways to improve treatment options for clinicians and to drive better patient care, working to complement our unrivalled portfolio of nephrology medicines with new technologies and treatment modalities to provide truly integrated solutions. The National Kidney Foundation is the leading organization in the U.S. Dedicated to the awareness, prevention and treatment of kidney disease for hundreds of thousands of healthcare professionals, millions of patients and their families, and tens of millions of Americans at risk. The provides the giving public with an easily recognizable symbol which certifies that the National Kidney Foundation meets the comprehensive standards of America's most experienced charity evaluator.|| © 2017 National Kidney Foundation, Inc., 30 East 33rd Street, New York, NY 10016, 1-800-622-9010. We subscribe to the HONcode principles of the Health on the Net Foundation.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
March 2018
Categories |